Co-administration of BJIKT with the anti-PD-L1 antibody leads to decreased positive PD-L1 on the tumor surface at post-treatment with each dose increment of BJIKT (from 28.8% to 24.6% between G3 and G5). This evidence concerns the gene CD274 and neoplasm.